Slide 1: Investor Presentation November 2024
Dimerix Investor Presentation November 2024 (o) LL Developing new therapies to treat inflammatory causes of kidney disease with unmet clinical needs Authorised for lodgement by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements nis presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks on important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from
Slide 3: Corporate overview
Corporate overview *Cash balance does not include: * $7.9 million - FY24 R&D tax incentive rebate received 15 November 2024 Ticker Symbol ASX: DXB 2 Cc Cash Balance (Sep24)* $19.2 million oO Market Capitalisation? “A$212 million 3 Share price! ~A$0.38 j= Total ordinary shares on issue? 557,833,583 j
Slide 4: Lead Drug Candidate
Lead Drug Candidate For personal use only • • FSGS Indication • • • Commercial and Technical Validation •
Slide 5: Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomer ulosclerosis (FSGS) GS? Focal =some Segmental = sections Glomerulo = of the kidney filtering units Sclerosis = are scarred How do you asure kidney function? * Historically, measured using “hard” endpoints for kidney disease (kidney failure) -which may not be reached for decade
Slide 6: Why are kidneys important? Symptoms of proteinuria
Why are kidneys important? Symptoms of proteinuria For personal use only • • • ➢
Slide 7: Significance of stabilising eGFR curve: primary endpoint
Significance of stabilising eGFR curve: primary endpoint Natural aging kidney * Kidney function can be measured using estimated function slope" = P glomerular filtration rate (eGFR): fo) o how many millilitres of blood is filtered by the oO” FSGS slope — kidney kidney per minute n function is crashi
Slide 8: Ongoing progress: PARASOL Biological Plausibility
1 Ongoing progress: PARASOL 2 Biological Plausibility ➢ ➢ For personal use only • • • • • • • 3 ACTION3 capturing all proposed endpoint data: eGFR and proteinuria Proteinuria eGFR slope Other endpoints • • • • • • •
Slide 9: DMX-200: Phase 2 met primary and secondary endpoints
DMX-200: Phase 2 met primary and secondary endpoints Of - : . A ‘ ‘ veoh 7 Clinically meaningful outcomes achieved for patients,? with no safety issues atgre Cc ai q 12) > y reduction in —_ 6 proteinuria could yield years oO _ VK of preserved native kidney Cc iL function and delay the [e) R- gh onse
Slide 10: For personal use only
For personal use only
Slide 11: Phase 3 Trial Timeline and Open Label Extension
For personal use only Background Phase 3 Trial Timeline Open Label Extension • • •
Slide 12: For personal use only
For personal use only • • • • • • •
Slide 13: For personal use only
For personal use only
Slide 14: Inflammatory modulator
For personal use only Inflammatory modulator
Slide 15: FSGS market
FSGS market a) FSGS is the most >2.600 Cc frequent primary fey glomerular disease Drs aaaetiesl| that reaches end-stage New diagnosed cases Of all diagnosed FSGS gS SP. y . o renal failure in the US! er year in US* cases globally are in US? Cp peed Euan Ih (7p) " PNY 9 y the world =) © Cc je) a . ,
Slide 16: Summary of DMX-200 licensing deals
Summary of DMX-200 licensing deals Dimerix has proven its ability to licence multiple territories, with more deals anticipated Summary ADVANZ ff PHARMA Other Licensing Deals (incl. US & China) pean For personal use sales EEA, Canada, Switzerland, United Arab Emirates (UAE), ) Territories Covered UK,
Slide 17: Key investment highlights
Key investment highlights For personal use only Global phase 3 trial underway Strong cash position Successful Phase 3 interim analysis Further licensing agreements anticipated 91% recruited for Part 2 analysis 2 Licensing deals successfully executed 2°¢ interim analysis anticipated “mid CY2025 0 app
Slide 18: For personal use only
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER OUR STRATEGIC PLAN ESG Statement SCAN ME Dimerix HQ 425 Sm
Slide 19: ACTION3 FSGS clinical study
ACTIONS FSGS CLINICAL STUDY > @ Dimerix
Slide 20: Board of Directors
For personal use only Mark Diamond Nina Webster Hugh Alsop Sonia Poli Clinton Snow BSc, MBA PhD, MBA (Exec), M.IP.Law BSc (Hons), MBA PhD BEng (Hons), BCom Non-Executive Chairman CEO & Managing Director Non-Executive Director Non-Executive Director Non-Executive Director Antisense (Percheron), Fauld
Slide 21: Executive management team
For personal use only Nina Webster Hamish George David Fuller Robert Shepherd Bronwyn Pollock PhD, MBA, M.IP.Law Bcom, CA, GIA (Cert) B. Pharm (Hons), MBBS PhD, MBA, BSc (Hons), MBA CEO & Managing Director CFO & Company Secretary Chief Medical Officer Chief Commercialisation Officer VP, Product Deve
Slide 22: Renal disease landscape
Renal disease landscape A squeaky wheel waiting for grease: 50 years of kidney disease management in the US” For personal use on Historical lack of incentives and public policy have Icontributed to high costs and} poor health outcomes for renal patients! 2018: workshops and regulatory acceptance of
Slide 23: Clinical study change: use of surrogate endpoints
Clinical study change: use of surrogate endpoints ACTING A surrogate endpoint is an intermediate outcome which substitutes the hard endpoint for a disease (e.g. kidney failure), which can take much longer to achieve FSGS CLINICAL STUDY FDA grants first accelerated approval drug based on proteinuria
Slide 24: Upfront payments in comparable licensing deals
$90 use only $80 Ventus+ Novo Nordisk (Worldwide) Ph 1, multiple assets $70 Travere Therapeutics +Vifor Pharma (EU, UK, ANZ) Ph 3, multiple indications $60 Roche +Ionis Pharmaceuticals Aurinia Pharmaceuticals + (Worldwide) Ph3, single asset Upfront payment (US$) Otsuka Pharmaceutical (EU, Japan, Rus
Slide 25: Policy change: renal disease healthcare economic burden
Policy change: renal disease healthcare economic burden D> a cS “40 million | fo) adults have kidney 7 disease (“15% of the . . : adult population) in the | Economic cost of kidney failure in the US US in 20211 Total Medicare expenses per year costs for kidney failure patients (2009-2021E) ? $60 © /
Slide 26: DMX-200 — working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) only fo) 12) =) © New Chemical Entity status, 2 x 120mg capsule daily Consistently safe and well 4 clinical studies com
Slide 27: For personal use only
For personal use only • • • Proposed non-clinical safety package suitability for NDA confirmed with FDA
Slide 28: For personal use only
For personal use only uMCR normalised to baseline v time N=7, GeoMean 50% 1.5 uMCR normalised 0% 1.0 -50% 0.5 On placebo On active 0.0 0 5 10 15 Time (weeks) • ▪ ▪
Slide 29: Intellectual property and exclusivity
Intellectual property and exclusivity 7/0 year Orphan 2 (@) 42 2032 exclusivity? n Method of Use Method of Use any territori (e) Granted? ny CCR2 inhibitor with ny ARB for any kidney disease Global application’ = any CCR2 antagonist with or. any endothelin A receptor for any disease Paediatri exclus
Slide 30: Advancing the broader pipeline
Advancing the broader pipeline Additional longer term pipeline opportunities diversify risk and potential sources of revenue For personal use only DMX-200 potential label DMxX-700 for Undisclosed Opportunities expansion respiratory/renal fibrosis Potential to expand DMX-200 into other rare Preclinic